Baseline characteristics of subjects randomized and treated
| . | INH . | Rosiglitazone . |
|---|---|---|
| n | 75 | 68 |
| Age (years) | 53.0 ± 10.7 (28–76) | 54.4 ± 11.0 (29–80) |
| Sex (M/F) | 48/27 | 31/37 |
| Ethnicity (white/other) (%) | 77/23 | 71/29 |
| C-peptide (pmol/ml) at screening | 1.09 ± 0.42 (0.36–2.05) | 1.11 ± 0.41 (0.40–2.15) |
| BMI (kg/m2) | 31.9 ± 4.7 (20–44) | 32.7 ± 6.6 (22–48) |
| Duration of diabetes (years) | 4.3 (0.08–22.0) | 3.1 (0.01–18.00) |
| A1C (%) | 9.5 ± 1.1 | 9.4 ± 0.9 |
| FPG (mg/dl) | 208 ± 56 | 199 ± 50 |
| 2-h PPG (mg/dl) | 293 ± 82 | 281 ± 71 |
| Total cholesterol (mg/dl) | 195.3 ± 38.3 | 199.9 ± 49.9 |
| HDL cholesterol (mg/dl) | 36.1 ± 8.7 | 40.1 ± 10.6 |
| LDL cholesterol (mg/dl) | 116.3 ± 31.8 | 119.4 ± 29.5 |
| Triglycerides (mg/dl) | 224.1 ± 193.8 | 194.3 ± 147.8 |
| . | INH . | Rosiglitazone . |
|---|---|---|
| n | 75 | 68 |
| Age (years) | 53.0 ± 10.7 (28–76) | 54.4 ± 11.0 (29–80) |
| Sex (M/F) | 48/27 | 31/37 |
| Ethnicity (white/other) (%) | 77/23 | 71/29 |
| C-peptide (pmol/ml) at screening | 1.09 ± 0.42 (0.36–2.05) | 1.11 ± 0.41 (0.40–2.15) |
| BMI (kg/m2) | 31.9 ± 4.7 (20–44) | 32.7 ± 6.6 (22–48) |
| Duration of diabetes (years) | 4.3 (0.08–22.0) | 3.1 (0.01–18.00) |
| A1C (%) | 9.5 ± 1.1 | 9.4 ± 0.9 |
| FPG (mg/dl) | 208 ± 56 | 199 ± 50 |
| 2-h PPG (mg/dl) | 293 ± 82 | 281 ± 71 |
| Total cholesterol (mg/dl) | 195.3 ± 38.3 | 199.9 ± 49.9 |
| HDL cholesterol (mg/dl) | 36.1 ± 8.7 | 40.1 ± 10.6 |
| LDL cholesterol (mg/dl) | 116.3 ± 31.8 | 119.4 ± 29.5 |
| Triglycerides (mg/dl) | 224.1 ± 193.8 | 194.3 ± 147.8 |
Data are means ± SD or means ± SD (range), unless otherwise indicated.